Advertisement
UK markets closed

  • NIKKEI 225

    38,471.20
    -761.60 (-1.94%)
     

  • HANG SENG

    16,248.97
    -351.49 (-2.12%)
     

  • CRUDE OIL

    85.47
    +0.06 (+0.07%)
     

  • GOLD FUTURES

    2,410.60
    +27.60 (+1.16%)
     

  • DOW

    37,849.43
    +114.32 (+0.30%)
     

  • Bitcoin GBP

    50,530.08
    -497.97 (-0.98%)
     

  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     

  • NASDAQ Composite

    15,888.92
    +3.90 (+0.02%)
     

  • UK FTSE All Share

    4,260.41
    -78.49 (-1.81%)
     
Money:

How to avoid tax creep in retirement

The state pension went up 8.5% in April, but frozen thresholds mean pensioners will be paying more tax

HMNC Brain Health to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

HMNC Brain Health
·2-min read

MUNICH, Germany, Sept. 07, 2021 (GLOBE NEWSWIRE) -- HMNC Brain Health (“HMNC” or the “company”), a clinical stage biopharma company pioneering the development of personalized therapies powered by predictive companion diagnostics, announced today that Chief Executive Officer, Benedikt von Braunmühl, Chief Clinical Development Officer, Dr. Hans Eriksson and Head of Operations, Dr. Maximilian Döbler will present at the H.C. Wainwright 23rd Annual Global Investment Conference. HMNC Brain Health’s virtual presentation will be available beginning Monday, September 13th at 7:00am Eastern Time through Wednesday, September 15th and is accessible through the following webcast link: https://journey.ct.events/view/573f15f1-a6b8-4ae4-96e2-3a586b52b0b8.

In addition, HMNC Brain Health’s management team will participate in virtual one-on-one meetings throughout the day. To schedule a meeting or to request further information on the conference, please contact your H.C. Wainwright representative.

A webcast of the presentation will be available on the HMNC Brain Health Website for 90 days through the above webcast link.

About HMNC Brain Health

HMNC Brain Health (HMNC Holding GmbH) is a biotech company pioneering in developing personalized therapies powered by predictive companion diagnostics, leading to far shorter treatments and higher remission. The company develops a unique pipeline for targeting both major depressive disorder (MDD) and treatment-resistant depression (TRD). HMNC Brain Health is located at one of the leading European biotech hubs in Munich and backed by renowned family offices. The company now enters the next stage of its development with a large-scale licensing and fundraising agenda.

ADVERTISEMENT

Media Contacts
Alexander Schmidt (Europe)
+49 151 22 99 39 765
alexander.schmidt@gaulyadvisors.com

Anne Donohoe (U.S.)
+1 212-896-1265
hmnc@kcsa.com

Investor Contact (U.S.)
Tim Regan / Rory Rumore
+1 347-487-6788
tregan@kcsa.com / rrumore@kcsa.com